Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
8-19-2015 12:00 AM

High Throughput Screening For Drug Discovery In Head And Neck
Squamous Cell Carcinoma
Morgan D. Black, The University of Western Ontario
Supervisor: Dr. Anthony Nichols, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Anatomy and Cell Biology
© Morgan D. Black 2015

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Translational Medical Research Commons

Recommended Citation
Black, Morgan D., "High Throughput Screening For Drug Discovery In Head And Neck Squamous Cell
Carcinoma" (2015). Electronic Thesis and Dissertation Repository. 3154.
https://ir.lib.uwo.ca/etd/3154

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

HIGH THROUGHPUT SCREENING FOR DRUG DISCOVERY IN HEAD AND
NECK SQUAMOUS CELL CARCINOMA
(Thesis format: Monograph)

by

Morgan Danielle Black

Graduate Program in Anatomy and Cell Biology

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Morgan D. Black, 2015

ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer
worldwide and despite advancements in traditional therapies, the survival rate of ~40%
remains unchanged, thus highlighting the need for novel treatments in HNSCC. High
throughput robotic screening of a panel of HNSCC cell lines was carried out against 1,505
compounds, where drug activity was measured using metabolic agent alamarBlue and
quantified by percent activity. Initial screening found that the majority of active compounds
could be grouped based upon their cellular target(s) and/or function including: cell cycle
regulation, cytoskeleton disruption, and DNA topoisomerase function. Potency was
confirmed with dose response curves for 23 hit compounds and ER27319 maleate and
NSC146109 hydrochloride were selected for further investigation. ER27319 maleate was
observed to control tumour growth in vivo. This systematic high throughput screen of large
panels of drugs identified a multitude of potentially effective agents for the treatment of
HNSCC.

Keywords: HNSCC, HPV, high throughput, drug screening, targeted therapy, precision
medicine, cell lines, spleen tyrosine kinase
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EPIGRAPH
“Research is what I'm doing when I don't know what I'm doing.”
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INTRODUCTION
Cancer is the leading cause of death worldwide, accounting for approximately 8.2

million deaths in 2012 [1]. According to the World Health Organization’s International
Agency for Research on Cancer, the number of new cancer cases is expected to rise about
70% over the next two decades. This predicted increase is based on both the growing
elderly population worldwide as well as the continued exposure to major risk factors of
cancer such as tobacco and alcohol use, unhealthy diet and physical inactivity [1].
Tobacco use continues to be the most important risk factor for cancer and is responsible
for about 20% of global cancer deaths annually [1].
Head and neck cancers comprise a group of malignancies that arise in many
different areas of the head and neck region including: the oral cavity, larynx, pharynx,
paranasal sinuses and nasal cavity as well as the salivary glands. Head and neck cancers
are currently the sixth most common cancer by incidence worldwide [2]. Tobacco and
alcohol use remain the two most important risk factors for head and neck cancers,
however, infection with human papillomavirus (HPV) has recently been recognized as an
important risk factor for some head and neck cancers, particularly oropharyngeal cancers
(OPC) involving the tonsils and base of tongue [3, 4, 5]. Over the next decade, HPVpositive OPCs are predicted to exceed the annual number of cervical cancer cases in the
United States [6]. This rise in OPCs has been observed by many different countries
worldwide, and presents a looming health concern for decades to come.
Currently, treatment of head and neck cancer is limited to chemotherapy,
radiation therapy and/or surgery. Unfortunately, despite advances in each of these
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treatment modalities, there has been no marked improvement in overall patient survival
thus highlighting the need for new therapeutic options.
This thesis focuses on identifying highly active agents that can suppress the
growth of head and neck cancer cell lines with the goal of identifying novel drug
compounds and cellular targets for the improved treatment of head and neck cancers.
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LITERATURE REVIEW

2.1 Cancer

Cancer is a complex disease in which cells of a specific tissue fail to respond to
signals that regulate cellular survival, proliferation, differentiation and death. As a result,
these non-responsive cells can accumulate and cause local disease [7]. Cancer cells have
been characterized as having six hallmark traits including: resisting cell death, sustaining
proliferative signaling, evading growth suppressors, activating invasion and metastasis,
enabling replicative immortality and inducing angiogenesis (Figure 1) [7]. More recently,
research has suggested that there are two additional hallmarks of cancer that are
emerging, with one involving reprogramming of cellular metabolism to support cancer
cell proliferation and the other which enables cells to evade destruction by the immune
system. In addition, inflammation and genome instability have been found to be
important factors that help enable tumour progression [7].
Cancer has long been understood to be a process of clonal evolution in which
rounds of clonal selection of distinct cancer cells within a tumour give rise to extremely
heterogeneous tumours [8]. This process of clonal expansion and selection leads to
genetic diversification within a tumour. For example, as cancer cells rapidly divide,
external pressures such as cytotoxic chemotherapy often select for clonal populations that
are highly mutated and/or resistant to treatment thus resulting in treatment-resistant
tumour cells with increased mutation rates and heterogeneity [8]. It has been observed
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Figure 1. The hallmarks of cancer.
This schematic includes the six hallmark features that enable cancer cell growth and
metastases. These hallmarks help provide a solid foundation for our current
understanding of basic cancer biology. Extensive research has been performed on each of
these six hallmarks to help improve our understanding of these processes as well as the
overall development and progression of a tumour. Addtionally, recent research has
suggested that two additional cancer hallmarks are emerging with one involving
reprogramming of cellular metabolism and the other which enables cells to evade
immunological destruction (adapted from Hanahan and Weinberg, 2011).
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that there is extensive genetic and phenotypic diversity both between tumours
(intertumour heterogeneity) and within an individual tumour (intratumour heterogeneity)
[9]. One of the major causes of both intertumour and intratumour heterogeneity in cancer
is genomic instability in these uncontrolled cancer cells, which results in increased
mutation rates and gene expression [9]. Heterogeneity in cancer has a tremendous effect
on treatment decisions and must be considered when attempting to optimize cancer
therapy and improve patient outcomes [9, 10].
There are over 200 different types of cancer that have been identified to date [11].
In 2014, over 190,000 new cases of cancer were diagnosed in Canada and of these,
approximately 76,000 (40%) resulted in death [12]. In order to help improve these
statistics, it is essential to remember that each individual cancer is unique and tumour
heterogeneity needs to be taken into consideration for improved cancer screening,
diagnosis, and prognosis as well as treatment decisions [8].

2.2 Head and Neck Squamous Cell Carcinoma
Head and neck cancers are the sixth most common cancer by incidence
worldwide, affecting approximately 600,000 new individuals each year [2].
Unfortunately, the mortality rate for advanced head and neck cancers remains at
approximately 40% with no significant improvement observed in the last few decades
[2]. Approximately 90% of head and neck cancers are squamous cell carcinoma,
originating in the epithelium of the upper aerodigestive tract [13]. Head and neck
squamous cell carcinoma (HNSCC) includes malignancies arising in many different sites
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Figure 2. Anatomy of the head and neck.
Head and neck cancers have a wide variety of primary site locations including the nasal
and oral cavities, larynx, paranasal sinuses, tongue, epithelium, salivary glands and the
pharynx (throat) which consists of three parts: the nasopharynx, oropharynx, and
hypopharynx (adapted from http://www.cancer.gov/types/head-and-neck).
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within the head and neck region including: the oral cavity, paranasal sinuses, nasal cavity,
tongue, lips, tonsils, salivary glands, pharynx, and larynx (Figure 2) [13].
Historically, HNSCC has long been associated with heavy tobacco use and
alcohol consumption, typically presenting in elderly males [13]. In Canada, the
government has invested millions of dollars into lowering the incidence of smoking over
the past few decades. Fortunately, these initiatives have proven successful with the
prevalence of smoking decreasing over 30% from 1965 (49.5%) to 2009 (18%) in both
male and females ≥15 years of age (Figure 3) [14]. With these declines in smoking, the
overall incidence of HNSCC has also been found to be decreasing. However, a subset of
HNSCC cases involving the oropharynx has risen dramatically (Figure 4) [5, 15]. This
rise in OPC has been shown to be caused by oral infection with HPV [5, 15].

2.3 HPV-positive HNSCC

Despite the overall reduction in HNSCC cases caused by tobacco use and alcohol
consumption, primarily attributed to government efforts to decrease smoking, a subset of
HNSCC cases involving the oropharynx have been found to be increasing in incidence
(Figure 4) [5, 15]. The cause of this increase is due to sexually transmitted oral infection
with HPV [15]. Unlike HPV-positive cervical cancers which are typically caused by
infection with high-risk HPV types including HPV type 16 and 18; HPV-positive OPC
are almost always caused by infection with HPV type 16 (90%+ of cases) [15]. The
reasons for this increase in oral HPV infection remain unclear; however, it is
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Figure 3. Smoking Declines in Canada.
This graph represents the percentage of Canadians who smoke, aged >15 years, on either
a daily or occasional basis, based on surveys collected by the federal government from
1965 to 2009 (adapted from Physicians for a smoke-free Canada, 2012).
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Figure 4. Frequency of HPV-positive and HPV-negative HNSCC cases.
Proportion of tonsillar carcinomas positive and negative for HPV during three sequential
time intervals from patient samples obtained at the London Health Science Centre in
London, Ontario, Canada, from 1993-2011. A rise in HPV-positive tonsillar HNSCC
cases was observed beginning in 2000 (adapted from Nichols et al., 2013).
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hypothesized that changes in sexual practices, specifically oral-genital contact, may be an
important factor [15].
This rise in OPC has been observed in the United States [17], Australia, Japan and
many other economically developed countries worldwide [18] and was also recently
shown by our laboratory to be occurring in Canada [5]. Approximately 25% of tonsillar
cancer cases in 1993 tested positive for HPV in a cohort of patients from Southwestern,
Ontario, Canada, as compared to the 62% of cases that were found to be HPV-positive in
2011 (Figure 4) [5].
Demographically, HPV-positive patients have been found to differ quite
substantially from the historical HPV-negative HNSCC patient seen in clinics who had a
long history of tobacco exposure and alcohol consumption. Patients with HPV-positive
tumours tend to be younger, healthier and have no history of smoking [19]. In addition,
these patients have a tendency to be more highly educated, affluent, and have had a
higher number of lifetime oral sex partners than HPV-negative patients [19].
Despite the increasing number of HPV-positive cases occurring worldwide, it has
been observed that patients with HPV-positive HNSCC have a better five-year overall
and disease-free survival prognoses than HPV-negative patients (Figure 5) [5]. Since
these patients are younger and healthier than patients with HPV-negative HNSCC and are
increasing in frequency, it is crucial that emerging treatments for HNSCC have maximum
benefits with minimal toxicity since these patients are more likely to be living with the
consequences of their treatment for years, or even decades to come.
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Figure 5. Overall survival for HPV-positive and HPV-negative HNSCC patients.
A survival analysis was performed using the Kaplan–Meier estimate comparing overall
and disease-free survivals of 95 patients in Southwestern, Ontario, Canada with either
HPV-positive versus HPV-negative oropharyngeal HNSCC tumours. HPV-positive
patients were found to have significantly improved five-year overall and disease-free
survivals as compared to patients with HPV-negative tumours (Nichols et al., 2013).
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2.4 Mutational Landscape of HNSCC

In January 2015, the Cancer Genome Atlas (TCGA) Network completed a
comprehensive genetic characterization of HNSCC, which included a multi-platform
analysis of 279 tumour-normal pairs (HPV-negative n=243, HPV-positive n=36)
including exome sequencing, copy number analysis, methylation expression arrays, and
RNA sequencing [20]. Genes previously known to be altered in HNSCC were confirmed
including: TP53, CDKN2A, PTEN, PIK3CA, and HRAS (Table 1) [20]. In addition,
alterations in genes not previously associated with HNSCC were also identified such as
loss of TRAF3 and amplification of E2F1 in HPV-positive tumours [20]. Finally, copy
number analysis using single-nucleotide polymorphism arrays detected previously known
CCND1 amplifications, CDKN2A deletions and more infrequent MYC, EGFR, ERBB2,
and CCNE1 amplifications [20].
In addition to identifying genetic alterations that were previously associated with
HNSCC as well as novel genetic variations, the mutational landscapes between HPVpositive and HPV-negative HNSCC tumours were found to differ immensely (Table 1)
[20, 21, 22]. This finding is consistent with the differing etiologies of HPV-positive and
HPV-negative HNSCC tumours. In HPV-negative malignancies, the disease is most often
caused by long-term exposure to tobacco as well as heavy alcohol consumption. Such a
cancer almost always has a mutated TP53 gene as well as an extensive number of
additional mutated genes including inactivated CDKN2A (Table 1) and amplification of
3q26/28 and 11q13/22 [20]. In contrast, HPV-positive HNSCC cases arise from the
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TSG1

PI3K

Oncogenes

Receptor tyrosine kinases

Table 1. Candidate therapeutic targets and driver oncogenic events in HNSCC.
Frequency of
alteration events
in HPV- (%)

Frequency of
alteration events
in HPV+ (%)

EGFR
FGFR1
ERBB2
IGF1R
EPHA2
DDR2
FGFR2
FGFR3
MET

15
10
5
4
4
3
2
2
2

6
0
3
0
3
6
0
11
0

CCND1

31

3

MYC

14

3

HRAS

5

0

PIK3CA
PTEN
PIK3R1
TP53
CDKN2A
NF1

34
12
1
84
58
3

56
6
3
0
3
0

1

TSG, tumour suppressor gene
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oncogenic action of viral oncoproteins, E6 and E7, which target essential, wild-type
tumour suppressors p53 and pRb, respectively, for degradation [15]. In HPV-positive
tumours, an inverse correlation has been observed between positive infection with HPV
and the mutation status of TP53 (Table 1) [20, 21]. As well, HPV-positive tumours were
found to be dominated by activating mutations and focal amplifications of PIK3CA
(56%), amplification of E2F1 (19%) and loss of TRAF3 (22%) [20].
Previous genetic characterizations of HNSCC have reported that the overall
mutation rate of HPV-positive tumours was approximately half that of HPV-negative
HNSCC malignancies (2.28 mutations/Mb and 4.83 mutations/Mb, respectively) [21],
however, the most recent and arguably most comprehensive data regarding the genomic
landscape of HNSCC concluded that the overall alteration rate did not differ significantly
by HPV status in HNSCC tumour samples [20]. Taken together, the differences in the
genetic profiles and etiologies between HPV-positive and HPV-negative HNSCC
tumours, present the possibility of novel molecular targets and/or pathways being
targeted for the treatment of HNSCC (Table 1).

2.5 High Throughput Drug Testing in HNSCC
Cell lines are imperfect models of cancer; however, they have proven to be
invaluable tools for cancer discovery. In 2012, two large studies performed by the Broad
Institute (identified forthwith as the Cancer Cell Line Encyclopedia [CCLE]) and the
Sanger Institute, involved screening a large number of cancer cell lines (947 and 639,
respectively) against drug panels and correlating genetic and expression data with drug
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response [23, 24]. These studies confirmed known drug correlations with molecular
findings, in addition to uncovering novel associations.
Unfortunately, only a small number of drugs were tested in both the CCLE and
Sanger studies (24 and 121, respectively) in a relatively small subset of available HNSCC
cell lines (31 and 21, respectively) [23, 24]. Using the limited information pertaining to
HNSCC, our laboratory interrogated data from Garnett et al. (2012), in an attempt to
identify drugs with increased efficacy in HNSCC cell lines [23, 25]. Four drugs, Afatinib,
Bosutinib, Docetaxel and Gefitinib, were found to have significantly higher activity in
HNSCC cell lines versus all other cancer cell lines tested (Figure 6) [25].
Docetaxel, an inhibitor of microtubule formation, is currently in routine clinical
use for the treatment of HNSCC. In addition, Afatinib and Gefitinib, were also identified
as preferentially active and both target epidermal growth factor receptor (EGFR), which
is currently the only approved target for the treatment of head and neck cancers using
Cetuximab [25]. The limited number of drug compounds tested in these large cancer cell
line screens greatly limits the ability of novel, highly active agents being identified in
HNSCC.
In addition, there were no HPV-positive HNSCC cell lines included in either of
these studies. The importance of testing HPV-positive cell lines, in addition to HPVnegative HNSCC lines, is absolutely critical given the fact that these cancers are
molecularly distinct (Table 1). An expanded, HNSCC-specific study including both
HPV-positive and HPV-negative HNSCC cell lines is needed, as well as an in vivo
validation of the most promising candidates, in order to improve patient outcomes.
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Figure 6. Compounds with increased activity in HNSCC cell lines.
Using the data published by the Sanger group in 2012, Nichols and colleagues (2014)
sought to identify drug compounds that demonstrated increased activity (lower IC 50
values) in HNSCC cell lines as compared to the remainder of the cancer cell line pool.
The four drugs listed above were found to be preferentially active in HNSCC cell lines
versus all other cancer cell lines screened (adapted from Nichols et al., 2014).
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2.6 Current Treatment of HNSCC

As mentioned previously, patients with HPV-positive tumours tend to be younger,
healthier and possess a greater chance of surviving their disease (Figure 5) [5, 19]. As
such, it is crucial that less harmful therapies are found for these patients, to help improve
their overall quality of life. Additionally, HPV-negative patients are still at significant
risk of cancer relapse and death (Figure 5) and also are at risk of severe treatment related
toxicity thus highlighting the need for improved treatments for both HPV-positive and
HPV-negative disease [2, 26, 27].
Contemporary treatments carry significant acute and late toxicities such as:
mucositis, pain, vomiting, swallowing difficulty, hearing loss, bone necrosis, stroke,
nerve injury and a risk of death of up to 3 % [27, 28]. It is evident that improved methods
are needed for treating HNSCC patients including differential and ideally personalized
treatment of HPV-positive versus HPV-negative tumours. Currently, only six drugs have
been approved by the United States Food and Drug Administration (FDA) for the
treatment of head and neck cancers including cytotoxic therapies such as cisplatin,
methotrexate, 5-flurouracil, bleomycin, docetaxel as well as a single targeted agent,
Cetuximab, which inhibits EGFR [26]. Our laboratory aims to develop a personalized
approach to the treatment of HNSCC through high throughput drug testing and
correlation of these results to the genomic alterations of the disease.
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2.7 Targeted Cancer Therapy
Targeted therapies in cancer are agents that interfere with specific targets (often
kinases) and/or pathways within cancer cells as opposed to non-selective traditional
therapies, which simply target rapidly dividing cells and are often associated with severe
toxicities. Targeted therapies are gaining traction in the development of anticancer drugs
and form the basis of precision medicine. Precision medicine is an emerging approach to
cancer therapy that involves the use of an individual tumour’s genetic profile to
specifically tailor and optimize drug treatment through utilization of targeted agents
found to target their specific genetic alterations [29]. An advantage of this type of
treatment is that the alterations that are suspected to be directly responsible for the growth
of a tumour are specifically targeted with an appropriate targeted therapy.
Many targeted therapies have been approved by the FDA for the treatment of
various cancers such as imatinib, which targets the constitutively activated BCR-Abl
protein in chronic myeloid leukemia (CML), trastuzumab, which blocks the function of
the estrogen receptor in breast cancers with HER2 amplifications and vemurafenib, which
targets the V600E activating mutation in BRAF for the treatment of melanoma and
thyroid cancer (http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies
/targeted-therapies-fact-sheet#q4). Many additional compounds are currently under
examination in clinical trials and even more are undergoing preclinical testing.
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2.8 Precision Medicine in HNSCC
To date, EGFR is the only approved target for the treatment of head and neck
cancers [25, 26]. Cetuximab, a monoclonal antibody therapy that inhibits EGFR, is
routinely used in the clinic for the treatment of HNSCC patients [26]. In addition to
EGFR, many novel targets and pathways are currently under investigation, in both
clinical trials and preclinical testing, for the treatment of HNSCC including: vascular
endothelial growth factor receptor (VEGFR), phosphatidylinositol-3-kinase (PI3K), Akt,
mammalian target of Rapamycin (mTOR), MET, and insulin-like growth factor receptor
(IGF-1R), for example [30]. The majority of molecules being investigated in these trials
are ones targeting cellular targets with previous associations to cancer with some having
been implicated as being important in HNSCC specifically, by recent publications of
genomic analyses of HNSCC cell lines and patient tumours.
One such target, PI3K, has been of interest to many researchers since activating
mutations and focal amplification of the PIK3CA gene, which encodes p110α, the
catalytic subunit of PI3K, are prominent in HNSCC, especially in HPV-positive tumours
(Table 1) [20]. Interestingly, when attempting to identify drugs with increased efficacy in
HNSCC from the large-scale high throughput drug screening performed by Garnett and
colleagues (2012), Nichols et al. (2014) found that AZD6482, a potent inhibitor of PI3kinase variant β, had significantly higher activity in PIK3CA mutant cancer cell lines as
compared to PIK3CA wild-type cancer cell lines [23, 25]. This is an excellent example,
teased out from a massive drug screening effort, of a targeted therapeutic agent having
the potential to be useful against a specific genetic alteration, in this case, mutations and
amplifications in the oncogene PIK3CA.
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2.9 Project Rationale
The prospect of precision medicine in the treatment of HNSCC is looking
increasingly more promising as progress is continuously being made in our understanding
of HNSCC genomics as well as in molecular pharmacology, thus leading to a rapid
expansion of new therapeutics being investigated [31]. Large-scale high throughput drug
screens, specific to HNSCC, are necessary in order to identify new agents that exhibit
increased activity in HNSCC cells and to identify novel cellular targets and/or pathways
that can be interrogated in HNSCC.
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3

HYPOTHESES AND OBJECTIVES

3.1 Hypotheses


High throughput drug screening of HPV-positive and HPV-negative
HNSCC cell lines will identify drugs that effectively control cell line
proliferation.



HPV-positive and HPV-negative HNSCC are molecularly distinct and will
differentially respond to a subset of therapeutic agents identified in a high
throughput drug screen.

3.2 Objectives


To identify drug compounds that are highly active in HNSCC cell lines
using a high throughput drug screening platform.



To confirm potency of top drug hits through generation of dose response
curves and determination of IC50 values.



To test a small subset of well characterized HNSCC cell lines against an
expanded panel of drug compounds.



To investigate the mechanism of drug action of two drug hits in vitro
using HNSCC cell lines.



To verify the effectiveness of Syk inhibitor, ER27319 maleate, at
controlling HNSCC cell line proliferation in vivo using a cell line
xenograft model.
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4

MATERIALS AND METHODS

4.1 HNSCC Cell Lines
Twenty-eight HNSCC cell lines were used in this study, the details of which can
be found in Table 2 along with their original source, all available clinical information as
well as their appropriate growth media. Each individual cell line was screened on the
high throughput platform in Toronto, Ontario at the same passage number for all drug
screens including the generation of dose response curves (see Sections 3.5 and 3.7).

4.2 Compound Libraries

A custom-made compound library from Tocris Bioscience comprised of 1,185
compounds and a proprietary kinase inhibitor library of 320 compounds (1,505
compounds total) was used for high throughput drug screening. Two additional libraries,
National Institutes of Health Clinical Collection and Prestwick compounds libraries were
also used as an expanded drug panel (1,825 compounds total) to screen a subset of 6 well
characterized HNSCC cell lines. All four compound libraries included compounds such
as anticancer agents and kinase inhibitors that have all been previously tested in humans
which helps to eliminate some regulatory hurdles for drug repurposing in HNSCC. The
libraries were prepared as 1 mM stock solutions in 100% dimethyl sulfoxide (DMSO)
and stored at –20°C in 384-well polypropylene plates (Sigma-Aldrich).
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Table 2. HNSCC cell lines used in this study.

Cell Line

HPV
Status

Tumour Site
(if available)

Patient
Information
(if available)

Growth Medium

Source

93-VU-147T

Positive

Floor of mouth

Male, T4N2

DMEM/F12

VUMC

HMS001

Positive

Oropharynx (tonsil)

Male

DMEM/F12

Harvard Medical School

UM-SCC47

Positive

Lateral tongue

Male, T3N1M0

DMEM/F12

University of Michigan

UPCI:SCC090

Positive

Oropharynx (tongue base)

Male, T2N0

DMEM/F12

University of Pittsburgh

UPCI:SCC154

Positive

Oral cavity

Male, T4N2

DMEM/F12

University of Pittsburgh

Cal27

Negative

Tongue

Male, 56

DMEM/F12

ATCC

Detroit 562

Negative

Pharynx

Female

DMEM/F12

ATCC

FaDu

Negative

Hypopharynx

Male, 56

DMEM/F12

ATCC

SCC-4

Negative

Tongue

Male, 55

DMEM/F12

ATCC

SCC-9

Negative

Tongue

Male, 25

DMEM/F12

ATCC

SCC-15

Negative

Tongue

Male, 55

DMEM/F12

ATCC

SCC-25

Negative

Hypopharynx

Male, 56

DMEM/F12

ATCC

SCC-61

Negative

------

------

DMEM/F12

Yale

Cal33

Negative

Tongue

Male, 69

DMEM+2mM L-glu

DSMZ

JHU006

Negative

------

------

DMEM/F12

Johns Hopkins

JHU011

Negative

Larynx

Male, T3N0

DMEM/F12

Johns Hopkins

JHU029

Negative

Oropharynx

Male, T4N0

DMEM/F12

Johns Hopkins

PCI6A

Negative

------

------

DMEM/F12

University of Pittsburgh

PCI6B

Negative

Oropharynx

Male, T3N3M0

DMEM/F12

University of Pittsburgh

PCI13

Negative

Oral cavity

Male, T4N1M0

DMEM/F12

University of Pittsburgh

PCI30

Negative

------

------

DMEM/F12

University of Pittsburgh

RF15A

Negative

------

------

DMEM/F12

University of Pittsburgh

RF22A

Negative

------

------

DMEM/F12

University of Pittsburgh

RF22B

Negative

Oral cavity

Male, T4N1M0

DMEM/F12

University of Pittsburgh

RF37A

Negative

------

------

DMEM/F12

University of Pittsburgh

RF37B

Negative

------

------

DMEM/F12

University of Pittsburgh

BICR56

Negative

Tongue

Female

DMEM+2mM L-glu

Public Health England

PE/CA-PJ49

Negative

Tongue

Male, 57

IMDM+2mM L-glu

Public Health England

DMEM, Dulbecco’s Modified Eagle Medium; VUMC, VU University Medical Center Amsterdam; ATCC,
American Type Culture Collection; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen;
IMDM, Iscove’s Modified Dulbecco’s Medium
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4.3 Short-tandem Repeat Analysis

Cell line identity was confirmed through short-tandem repeat (STR) profiling at
The Centre of Applied Genomics in Toronto, Ontario, Canada, to ensure that there had
been no contamination of the cell lines. All cell lines with published STR profiles were
confirmed to be correct (Appendix 1).

4.4 HPV Infection Status

Confirmation of HPV (type 16) infection status in HPV-positive HNSCC cell
lines was confirmed by quantitative reverse transcription PCR (RT-PCR) using primers
designed to target HPV type 16 and GAPDH transcripts (Table 3). HMS-001, UMSCC47, 93-VU-147T, UPCI:SCC090 and UPCI:SCC154 were all confirmed to be
positive for HPV type 16, which is consistent with the literature.

Table 3. RT-PCR primers used in this study.
Target

Oligonucleotide Sequence

Notes

HPV-16
HPV-16
HPV-16
TP53
TP53
TP53
GAPDH
GAPDH
GAPDH

TTGCAGATCATCAAGAACACGTA
GTAGAGATCAGTTGTCTCTGG
AATCATGCATGGAGATACACCTACATTGCATGA
CTCAGCATCTTATCCGAGTGGAAG
TGGTACAGTCAGAGCCAACCTCA
CCCTATGAGCCGCCTGA
GCTCATTTGCAGGGGGGAGCC
CTGATGATCTTGAGGCTGTTG
TCTGCCCCCTCTGGTCATGCCCCCATGTTCGTCATGGGA

HPV forward primer
HPV reverse primer
HPV probe (JOE)
TP53 forward primer
TP53 reverse primer
TP53 probe (FAM)
GAPDH forward primer
GAPDH reverse primer
GADPH probe (Cy5)
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4.5 High Throughput Drug Screening

All high throughput screening in this study took place at the S.M.A.R.T Facility
in the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto, Ontario,
Canada.
Cells were seeded five days prior to screening. Cells were then transported to
Mount Sinai Hospital. Each HNSCC cell line was passaged twice prior to screening in
their appropriate growth medium (Table 2) (Wisent Bioproducts, St-Bruno, Quebec)
supplemented with 10% fetal bovine serum (FBS) (Wisent Bioproducts), 1%
hydrocortisone (Multicell) and 100mg/mL penicillin and 100U of streptomycin (Wisent
Bioproducts). Cells were then transported in a T175 flask (Sarstedt, Nümbrecht,
Germany) filled completely with appropriate media since the entire cell line panel is
adherent. Upon arrival in Toronto, all but approximately 30 mL of media was transferred
into a sterile flask and used as cell resuspension media for cell seeding.
The following day, cells were washed with phosphate-buffered saline (PBS)
(Wisent Bioproducts) and trypsinized (Wisent Bioproducts), resuspended to a
concentration of 12,000 cells/mL and 50μL (600 cells/well) were seeded (Beckman
BioMek FX, Mississauga, Ontario) into black 384-well clear-bottom plates (Corning®,
Flintshire, United Kingdom). Each 384-well plate also had cells only and media only
control wells on the two outer columns of the plate, respectively. Once seeded, cells were
incubated at 37°C and 5% carbon dioxide for 24 hours. Following incubation, cells were
treated with drug (1 compound/well) using an automated drug pinning device (Beckman
Multimek, Mississauga, Ontario). For screening of the compound libraries, all 3,330
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compounds screened were tested at a single, final concentration of 4 μM. For the 23
compounds selected for hit confirmation, 10 different drug concentrations were tested
ranging from 15 nM to 8 μM. Cells were incubated with the drug compounds for 48
hours at 37°C and 5% carbon dioxide (Figure 7).

4.6 AlamarBlue Viability Assay
AlamarBlue (Life Technologies, Burlington, Ontario) is a metabolic agent that is
reduced by increased mitochondrial activity in viable cells [32]. AlamarBlue uses the
natural reducing power of live cells to convert its inactive ingredient resazurin (blue,
indicating non-viable cells) to its active form, resorufin (red, indicating viable cells),
which generates a quantitative measure of cytotoxicity and viability [32]. Following
addition of drug on day 1 of high throughput drug screening and the 48 hour incubation
period, alamarBlue was added to each well (5%) (Beckman BioMek FX) and allowed to
incubate for 4 hours (Figure 7). Fluorescence signals were then measured using a
Pherastar microplate reader (BMG Labtech, Ortenburg, Germany) with peak excitation at
570 nm and peak emission at 585 nm. For determination of drug activity, the average of
all media only control wells was subtracted from all test wells and the percent of drug
activity, whether positive or negative, was then determined by calculating the change in
fluorescence values between treated cells and untreated cells.
The top 5% (78/1,505) of compounds found to display the greatest average
percent reduction in cellular growth across the entire HNSCC cell line panel were
deemed hit compounds (Appendix 2).
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Figure 7. Protocol for high throughput drug screening of HNSCC cell lines.
Cell lines were seeded from frozen stocks and passaged twice prior to screening. Cells
were seeded at 12,000 cells/mL in 384-well plates and allowed to incubate for 24h at
37°C and 5% CO2. On day 1, drug compounds were added to each well at a final
concentration of either 4 μM or 10-point concentrations ranging from 15nM to 8 μM and
incubated under the same conditions. After 48h, cells were treated with alamarBlue,
incubated for 4h at 37°C and 5% CO2 and fluorescence measurements taken. Untreated
cell wells were used as a baseline for cellular proliferation.
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4.7 Dose Response Curves
Following the drug screening methodology described above, 23 of the 78 hit
compounds (Appendix 2) were selected for drug validation based on three criteria:
universal potency (compounds that were broadly effective across majority of cell lines),
differential activity (compounds that were extremely potent in some cell lines while
completely ineffective in others) and compounds affecting the PI3K/Akt/mTOR pathway.
HNSCC cell lines underwent the identical drug screening methodology as
described above (Figure 7), however, on day 1, drugs were added at 10 doses in the range
of 15 nM to 8 μM for the 23 drug compounds selected for validation. Cells were then
incubated under the same conditions for 48h at which point florescence readings for cell
viability were measured and data collected. Cell viability in my assays was measured
with alamarBlue (Life Technologies). Absorbance measurements were taken and dose
response curves were calculated for these top hits to confirm compound activity in vitro
in HNSCC cell lines. The IC50 (half maximal inhibitory concentration) for each agent was
then determined by sigmoidal regression using GraphPad Prism v6.0. In cases where an
IC50 value could not be definitively extrapolated, the normalized raw data was examined
to determine a drug sensitivity dose range. In rare cases, drug sensitivity data could not
be converged using non-linear regression so no conclusions on drug sensitivity in these
cases could be drawn.
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4.8 Western Blot Analysis

Cal27 cells were seeded prior to the experiment in T25 flasks (Sarstedt). Cells
were then treated with ER27319 maleate (0.62 μM) for 0.08, 0.16, 0.33, 1, 3, 6, 12, 24, or
48 hours. An additional flask was maintained as an untreated control. Cells were lysed at
each time point in lysis buffer containing radioimmunoprecipitation assay (RIPA) buffer
and protease inhibitor (1:250). Total protein content was quantified using a protein assay
reagent (BioRad) in a Bradford assay. Equal amounts of protein (40 μg) were resolved on
a 4-12% gradient SDS-polyacrylamide gel (Life Technologies). The separated proteins
were then transferred to a nitrocellulose membrane (GE Healthcare, Toronto, Ontario)
and blocked for 1 hour at room temperature with either 5% w/v milk (Bioshop,
Burlington, Ontario) or 5% w/v bovine serum albumin (Sigma-Aldrich, Oakville,
Ontario), for total and phosphorylated protein, respectively. The membrane was then
incubated with primary antibody (Table 4) (1:1000) overnight at 4°C followed by
incubation with the secondary, goat anti-rabbit-

Table 4. Antibodies used in this study.
Antibody Label

Molecular
Weight (kDa)

Host Species
(Isoform)

Commercial Source

Dilution
Used

Syk (D3Z1E)
Phospho-Syk (Tyr323)
Phospho-Syk (Tyr525/526)
Anti-Rabbit IgG
α-tubulin
Anti-goat

72
72
72
--50
--

Rabbit
Rabbit (IgG)
Rabbit
Goat
Mouse
Donkey

Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Sigma-Aldrich
Jackson Laboratories

1:1000
1:1000
1:1000
1:5000
1:2000
1:5000
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horseradish peroxidase (HRP) (Cell Signaling, Danvers, Massachusetts) (1:5000) for 1
hour

at

room

temperature.

Finally,

membranes

were

developed

using

a

chemiluminescence reagent (Millipore Luminata® Crescendo, Etobicoke, Ontario). To
ensure equal loading for each lane, membranes were stripped, re-blocked, probed with α–
tubulin (1:2000) and incubated with goat anti-mouse-HRP (1:5000) for 1 hour at room
temperature and then developed in the same manner described previously.

4.9 Quantitative Reverse Transcription PCR
Endogenous transcript levels of TP53 were measured, using quantitative RT-PCR,
to verify that cellular transcript levels were increasing upon treatment with NSC146109
hydrochloride. Cal27 cells were seeded prior to the experiment in T25 flasks (Sarstedt).
The following day, cells were treated with NSC146109 hydrochloride (0.98 μM) for 0.5,
1, 3, 6, 12, 24, or 48 hours. An additional flask was maintained as an untreated control.
Cells were lysed at each time point using QuickExtract RNA extraction kit (Epicentre,
Madison, Wisconsin) to obtain RNA. This RNA was for construction of complementary
DNA (cDNA) by reverse transcriptase PCR. This cDNA was then used as template in a
multiplex quantitative PCR reaction (QuantiTect Multiplex PCR Kit, Qiagen, Toronto,
Ontario) using primer and probes designed to target TP53 (Solaris, GE Dharmacon,
Ottawa, Ontario) and GAPDH transcripts (Table 2).
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4.10 Cell Line Xenografts
Cal33 were seeded from frozen stocks in Dulbecco’s Modified Eagle Medium
(DMEM) (Multicell) supplemented with heat inactivated FBS (Multicell), 1%
hydrocortisone (Multicell) and 100mg/mL penicillin and 100U of streptomycin
(Multicell). After initial cell seeding, cells were maintained in complete media without
antibiotics. Cells were collected, spun down and resuspended in PBS (Multicell). Eight
week old BALB/c athymic mice (Charles River, Sherbrooke, Quebec) were obtained and
1 x 106 cells in 100 uL in PBS were injected into each flank (2 injections per mouse).
Mice were monitored until tumours were palpable (8 days) at which time tumours were
measured for a tumour baseline evaluation and drug treatment was initiated. There were
10 mice for each of the 3 treatment groups: vehicle control dose, 10 mg/kg dose, and 40
mg/kg (Table 5).
ER27319 maleate was administered at 10 mg/mL and 40 mg/mL doses by oral
gavage along with the control group receiving PBS by oral gavage (Table 5). Mice were
dosed daily (5 days/week) and tumours measured twice a week with digital calipers
(Mitutoyo, Japan). ER27319 maleate treatment continued until day 26, at which time
mice were sacrificed by CO2 asphyxiation. Visible tumours, along with the liver, spleen,
heart and lungs were collected and formalin fixed for preservation of tissue for potential
investigations in the future.
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Table 5. Dosing regimens for in vivo cell line xenografts.

Treatment Group

Dose (mg/kg)

Placebo (PBS)

---

ER27319 maleate

10

ER27319 maleate

40

# of Mice
per group

Treatment
Schedule

Termination

10

Daily oral
gavage
(5 days/week)

All mice were sacrificed
at day 26 of ER27319
maleate treatment

33

5

RESULTS

5.1 Large-scale, high throughput drug screening identified
highly active agents in HNSCC cell lines
Of the 1,505 compounds screened, 78 drugs were observed to reduce cellular
growth by greater than 20% in at least 25% of HNSCC cell lines screened (top 5% of
active compounds screened) (Appendix 2).

These compounds were deemed ‘hit’

compounds and found to be active in HNSCC cell lines.
The list of compounds was then narrowed down 23 hit compounds to move
forward for drug validation studies (Table 6), based on three criteria: universal potency
(compounds that were extremely potent across majority of the cell line panel), differential
activity (compounds that were highly active in some cell lines while completely
ineffective in others) or compounds affecting the PI3K/Akt/mTOR signaling pathway (a
frequently altered pathway in HNSCC cells) (Table 1). These 23 hit compounds were
selected for validation based upon the above criteria as well as their potential as
therapeutic agents in other malignancies as described in the literature.
Dose response curves were generated (Figure 8) for each of the 23 compounds in
28 HNSCC cell lines and IC50 values were determined (Figure 9). Validation of these 23
drug hits proved successful as the majority of compounds remained highly active (IC 50 <
2 μM) in the validation step of my high throughput drug screening (Figure 9).
Additionally, the trends of universal potency as well as differential activity, two of the
criteria used for selection of these compounds for validation, were found to continue
upon determination of drug sensitivity in these cell lines (Figure 9).
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Table 6. Drug hits selected for drug validation studies.

PI3K-pathway
specific

Differential Activity

Universal Potency

Selection
Criteria

1

Drug

Target

Pyrrolidinedithiocarbamate ammonium
NSC146109 hydrochloride
Ro 31-8220 mesylate
Ouabain

NF-kB
p53
PKC
Na,K-ATPase
δ1 opioid
receptor
GABAA
Syk
NOP receptor
CDK4
c-JNK
Cdc25
PAR1
Wee1
Chk1,2
Bcr-Abl, Src
FGFR
MET,
VEGFR2
MEK
PI3k/mTOR
PI3K
mTOR
AKT
PI3K

BNTX maleate
SCS
ER27319 maleate
JTC 801
Ryuvidine
BI 78D3
NSC 95397
SCH 79797 dihydrochloride
MK-1775
TCS2312 dihydrochloride
Bosutinib
AZD4547
Foretinib
RDEA119
NVP-BEZ235
GDC-0941 bismesylate
Rapamycin
A-443654
BYL719

NF-kB
p53 levels
Signalling
Ion channels

Clinical Trial
status
(# in HNSCC)1
0
0
6
3

Opiod receptor

0

NTM Receptor
Immune signalling
Opiod receptor
Cell cycle
MAPK Signalling
Cell cycle
Platelets; T cells
Cell cycle
Cell cycle
Signalling
Signalling

0
0
0
0
0
0
0
21(2)
3
35
10

MAPK Signalling

11(1)

MAPK Signalling
PI3K/AKT/mTOR
PI3K/AKT/mTOR
PI3K/AKT/mTOR
PI3K/AKT/mTOR
PI3K/AKT/mTOR

3
22
17
1759(41)
0
30(6)

Pathway/Target
Affected

Refers to the total number of publicly and privately supported clinical studies of human participants that
are currently ongoing as of June 20, 2015 with the number in parentheses referring to the number of trials
intervening with head and neck cancers (www.clinicaltrials.gov).
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IC50 = 1.49

IC50 = 1.54

IC50 = 3.31

Figure 8. Representative dose response curves from drug screening for hit
confirmation.
A. Examples of dose response curves with a sigmoidal decrease in percent activity of cell
growth where IC50 values could be confidently extrapolated from the modeled data.
B. Examples of dose response curves that were found to be ambiguous meaning that
specific IC50 values could not be calculated from this modeled data. In these situations,
normalized raw data was reviewed and a drug sensitivity concentration range was
determined to resolve the sensitivity of a particular cell line. In some cases the raw data
simply could not be resolved and the result was ‘not converged’ where Prism could not
converge a line of best fit to the data.
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Figure 9. Sensitivity of HNSCC cell lines to 23 compounds identified by high
throughput drug screening.
Ten-point dose response curves were generated for 23 drug compounds identified as
being highly active in the HNSCC cell line panel where cellular viability was measured
using alamarBlue. Criteria for how drugs were selected can be seen along the left. IC 50
values, in micromolar, for each agent were determined by non-linear regression. HPVpositive HNSCC cell lines are denoted as pink and compounds selected for preclinical
development in blue. Green represent exquisite sensitivity (IC 50 < 2 μM), yellow are
moderately sensitive (IC50 = 2-7.99 μM) and grey are resistant (IC50 > 8 μM, which was
the highest concentration tested). Hatched squares represent data that was not converged,
which occurs when non-linear regression cannot converge on a line of best fit.
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5.2 HNSCC cell lines are sensitive to known
chemotherapeutics
A subset of 10 compounds identified in the list of 78 hit compounds were found
to be well-established chemotherapeutic agents that are currently, or have been routinely
used in the treatment of various cancers, including head and neck cancers (Table 7;
Appendix 2). Drugs such as daunorubicin, vincristine sulfate, etoposide, and irinotecan
are used for the treatment of different malignancies and were found to be highly active in
HNSCC cell lines (http://www.cancer.gov/about-cancer/treatment/drugs). In addition,
doxorubicin and paclitaxel were identified as drug hits and were/are clinically used for
the treatment of head and neck cancers specifically. These compounds were found to be
extremely efficient at controlling HNSCC cell line proliferation in vitro, many of which
displayed high activity across the majority of the cell line panel.
Although 10 known chemotherapeutic drug compounds were found to be active in
the current screen, it was observed that some of these clinically-used compounds were
not as effective as many other hit compounds (Appendix 2). For example, the drug
Taxol® (paclitaxel, NSC125973) was found to be one of the 78 hit compounds; however,
a multitude of other compounds that were screened displayed much higher activity across
the panel of HNSCC cell lines (Appendix 2). Additionally, both cisplatin and carboplatin,
which are the most frequently used chemotherapeutics in HNSCC, were included in my
drug screening at 4 μM but were not identified as hits using my selection criteria.
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Table 7. Hit drug compounds currently used for the treatment of cancer.

Drug Name

Cellular Pathway
and/or Target

Number of Clinical
Trials (head and neck
specific)

Treatment Uses in Cancer

Alternate
Drug Name(s)

Actinomycin D

RNA polymerase

46

Ewing’s sarcoma, testicular,
melanoma, soft tissue sarcoma
etc

------

Camptothecan

DNA topoisomerase I

1223 (68)

Colon, rectal

Irinotecan

Clofarabine

DNA/RNA synthesis

149

ALL1

------

Daunorubicin

DNA/RNA synthesis

248

ALL, AML2

------

Doxorubicin

DNA topoisomerase II

1576 (15)

Bladder, breast, head and neck,
liver, lungs, ovary, thyroid etc

------

Etoposide

DNA topoisomerase II

1135 (5)

Testicular, bladder, prostate,
lung, stomach, uterine

------

Homoharringtonine

Protein synthesis

18

CML3

Omacetaxine
mepesuccinate

Taxol

Microtubules

2482 (210)

Breast, ovarian, lung, bladder,
prostate, head and neck,
melanoma etc

Paclitaxel,
NSC 125973

------

------

Vinblastine sulfate

Microtubules

230 (2)

Hodgkin’s disease, nonHodgkin’s lymphoma,
testicular, breast, lung, head
and neck, bladder etc

Vincristine sulfate

Microtubules

861 (1)

Acute leukemia, multiple
myeloma, thyroid etc

1

ALL, acute lymphoblastic leukemia; 2AML, acute myelogenous leukemia; 3CML, chronic myelogenous
leukemia.

39

5.3 HNSCC cell lines are sensitive to drugs targeting wellknown pathways and targets in cancer
The majority of drug hits identified in the high throughput screen could be
grouped together based upon the pathway(s) and/or target(s) they are known to affect
within the cell (Figure 10). Many of the targets and pathways found to be affected by the
top hits were ones that have been previously implicated in cancer and HNSCC in
particular. Some of the most prominent targets within the top drug hits were compounds
interfering with the function of various receptor tyrosine kinases (RTK) including EGFR
and VEGFR. Additionally, compounds affecting cell cycle regulation, cytoskeleton
assembly, NF-κβ signaling, and DNA topoisomerase function were all found to be highly
active in HNSCC cell lines (Figure 10). As well, drug compounds found to inhibit protein
kinase C (PKC) and interfere with protein synthesis were found to be highly active.

5.4 High throughput screening identified highly active
agents targeting novel cellular targets in HNSCC
In addition to identifying targets and pathways previously associated with cancer,
and HNSCC specifically, several novel targets were also identified in HNSCC cell lines
(Appendix 2). Such novel HNSCC targets included: protease-activated receptor (PAR1),
transient receptor potential cation channel subfamily V member 1 (TRPV1), somatostatin
receptor 4 (sst4), nociceptin receptor, SETD8, GABAA receptor, interleukin 8 receptor
beta (CXCR2), p38α, excitatory amino acid transporter (EAAT2/4), N-methyl-D-
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Figure 10. Hit compounds categorized based upon their cellular target(s).
HNSCC cell lines were screened, in duplicate, according to the methodology described in
Figure 7. Compounds that were active in at least 25% of the HNSCC cell line panel, in
both experimental replicates, were classified as ‘hits’. Seventy-eight hits were identified
as drug hits (Appendix 2) and could be grouped based on the pathway(s) and/or target(s)
they are known to affect within the cell, as shown above.
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aspartate receptor (NMDA), fatty acid amide hydrolase (FAAH), retinoic acid receptor
gamma (RARγ) as well as compounds that were anthelmintics, dopamine receptor
antagonists and inhibitors of DNA methylation (Appendix 2, 3). All of these compounds
were found to display activity in vitro throughout the HNSCC cell line panel.

5.5 Select HNSCC cell lines were less sensitive to
chemotherapeutics
Many of the HNSCC cell lines that were tested displayed patterns of extreme to
moderate sensitivity to the top 30 of 78 compounds tested (Appendix 2). In contrast, 3
HNSCC cell lines, SCC-4, SCC-25 and PCI6A, were found to be strikingly less sensitive
to many of the top 78 compounds. These cell lines were observed to have similar raw
fluorescence intensity values as all other HNSCC cell lines screened when left untreated
thus inferring comparable cellular growth. Additionally, these cell lines displayed this
insensitivity trend in both experimental replicates. SCC-25 continued to be relatively less
sensitive than the remainder of the HNSCC cell line panel when treated with the top 23
drug compounds selected for validation (Figure 9).
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5.6 Expanded screening identified compounds with
preferential activity in either HPV-positive or HPV-negative
HNSCC cell lines
With the knowledge that HPV-positive and HPV-negative HNSCC tumours arise
by distinct mechanisms and possess differing genetic landscapes (Table 1), as previously
discussed, I expected to uncover compounds that were exclusively active in either HPVpositive or HPV-negative HNSCC cell lines. However, from the preliminary screening
and initial hit list, I was unable to identify any compounds that displayed any significant
preferential activity in either HPV-positive or HPV-negative cell lines.
To help resolve this, I performed an expanded drug screen of 1,825 additional
compounds against a subset of HNSCC cell lines, including both HPV-positive and HPVnegative lines. Hits were classified as compounds that had a B score, which is a variation
of a Z score that takes into account positional plate errors, that was 3 standard deviations
below the experimental mean of cellular proliferation (Appendix 3). From the hit list that
was generated, 5 compounds were found to be preferentially active in HPV-negative cell
lines while only one compound, hycanthone, was found to be exclusively active in 2 of
the 3 (93-VU-147T and HMS001) HPV-positive cell lines tested (Table 8, Appendix 3).
Hycanthone exhibited negligible activity in all three HPV-negative HNSCC cell lines
tested. There is some literature investigating this compound, however, it does not appear
to have been explored in context of head and neck cancers thus providing a potential
avenue for further research in HNSCC.
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Table 8. Drug compounds with preferential activity in either HPV-positive (pink) or
HPV-negative (white) HNSCC cell lines.
Drug Name

Function/Target

HNSCC cell line
specificity

Puromycin dihydrochloride
6-azauridine
Primaquine diphosphate
Rosiglitazone maleate
Letrozole
Hycanthone

Antibiotic
Anti-viral
Anti-parasitic
Anti-diabetic
Aromatase inhibitor
DNA/RNA synthesis

HPV-negative
HPV-negative
HPV-negative
HPV-negative
HPV-negative
HPV-positive

5.7 NSC146109 hydrochloride effectively inhibited HNSCC
cell line growth in vitro
NSC146109 hydrochloride was identified as highly active across the HNSCC cell
line panel with an average reduction in cellular growth of approximately 84% (Appendix
2). Based on its universal potency in the cell line panel, as well as its role in reactivating
p53 [33], this compound was selected as one of the 23 compounds to move forward for
drug validation studies (Table 6, Appendix 2). Dose response curves were generated and
IC50 values calculated for all HNSCC cell lines against NSC146109 hydrochloride and
not unexpectedly, every cell line in the panel was found to be sensitive; with the majority
of cell lines having IC50 values below 2 μM (Figure 9).
Quantitative RT-PCR was performed in an attempt to quantify TP53 levels in
both treated and untreated Cal27 cells. Control GAPDH transcripts could be efficiently
detected using quantitative PCR, which indicates that the RNA extraction and cDNA
production protocols were both successful, as seen in Figure 11. Unfortunately, TP53
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Figure 11. Representative amplification plots of TP53 and GAPDH transcripts.
Cal27 cells were treated with NSC146109 hydrochloride (0.98 μM), cells were lysed and
RNA collected at multiple time points. Complementary DNA was then generated by RTPCR. This cDNA was then used as template in a multiplex quantitative PCR reaction
using primer and probes designed to target TP53 (red) and GAPDH (black) transcripts.
Endogenous transcript levels of TP53 were measured in an attempt to verify that cellular
transcript levels increased upon treatment with NSC146109 hydrochloride. The above
amplification plots are representative of all amplification curves for both GAPDH and
TP53 where GAPDH could be successfully detected, thus indicating successful RNA
extraction, cDNA production and qPCR. Unfortunately, TP53 transcripts were not
efficiently detected in any sample tested.
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transcript levels were too low to be detected at all time points in both treated and
untreated samples, so no conclusions could be made regarding the effect of NSC146109
hydrochloride treatment on TP53 transcript levels in Cal27 HNSCC cells in vitro (Figure
11).

5.8 ER27319 maleate potently suppressed HNSCC cell line
proliferation in vitro
ER27319 maleate was identified as a highly potent compound following initial
screening of my HNSCC cell line panel. On average, this compound was found to reduce
cellular growth by approximately 77% of the HNSCC cell lines screened (Appendix 2).
This compound was selected as one of the 23 compounds to move forward for drug
validation studies (Table 6) based on the high activity observed at a single dose in
preliminary screening (Appendix 2). Dose response curves were generated and IC50
values calculated for ER27319 maleate against all HNSCC cell lines. Almost every
HNSCC cell line tested was found to be sensitive with the majority of lines having IC 50
values below 3 μM (Figure 9).
Next, I sought to investigate the cellular mechanism of ER27319 maleate in
HNSCC cell lines in vitro by examining spleen tyrosine kinase (Syk) phosphorylation in
the presence and absence of ER27319 maleate with western blot analysis [34].
Endogenous Syk was detected at all time points in both the presence and absence of drug
(Figure 12). Protein loading was observed to be sufficient and uniform based on tubulin
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Figure 12. Effects of ER27319 maleate on phosphorylation of Syk.
Cal27 cells were treated with ER27319 maleate at 0.62 μM for 0.08, 0.16, 1, 3, 6, 12, 24,
or 48 hours. An additional flask was maintained as an untreated control. Cells were lysed
and equal amounts of protein were loaded into each well. Phosphorylated Syk was probed
for using two antibodies; however, phosphorylated Syk in untreated samples was not
detectable so no conclusions could be confidently drawn. Levels of endogenous Syk were
also examined and tubulin was used as a loading control.
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detection; however, I was unable to adequately visualize many of the potential
phosphorylated Syk proteins. Although it initially appeared as though addition of
ER27319 maleate was inhibiting Syk phosphorylation at both early and late time points
(0.08, 24, 48 hours at the Y525/526 phosphorylation sites); untreated phospho-Syk was
not detected, so no conclusions regarding the effect of ER27319 maleate on Syk
phosphorylation could be definitively drawn (Figure 12).

5.9 ER27319 maleate suppressed tumour growth in vivo
Using Cal33 cell line xenografts, ER27319 maleate was orally administered at 10
mg/kg and 40 mg/kg doses. Mice were dosed daily for 26 days with tumours measured
twice weekly (Table 5). ER27319 maleate was found to be extremely well tolerated, at
both doses, by all mice tested. For all tumour measurements taken (days 5-26), paired
Student’s t-tests were performed comparing the average percent increase in tumour
volume (mm3) for both doses of ER27319 maleate-treated tumours to untreated control
tumours (Table 9). Mice treated with ER27319 maleate at 40 mg/kg were found to have
significantly decreased percent increase in tumour growth as compared to control
tumours for every tumour measurement taken (Figure 13).
Additionally, mice treated with low dose ER27319 maleate (10 mg/kg) were
observed to have significantly decreased tumour growth as compared to untreated mice at
days 5, 8, 19, and 22. This inhibition in tumour growth provides excellent support for my
in vitro drug screening and serves as a starting point where I plan to test higher doses of
ER27319 maleate to see if tumour growth can be further decreased or even halted
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completely. Preliminary investigation into ER27319 maleate at a dose of 70 mg/kg (n=5)
found that the dose was tolerated well over 6 days of treatment.

Table 9. Mean tumour volumes and standard errors as percent increase from
untreated baseline tumour measurements.
Day of
ER27319 maleate
Measurement

Control
(% increase)

10 mg/kg
(% increase)

40 mg/kg
(% increase)

5

40.8 ± 12.6

-3.6 ± 7.3*

-21.2 ± 8.6***

8

67.2 ± 14.0

20.3 ± 10.0**

-0.7 ± 13.7**

12

121.7 ± 25.1

63.1 ± 15.6

10.7 ± 15.2**

15

180.0 ± 31.3

109.1 ± 16.4

30.6 ± 17.1***

19

225.6 ± 36.8

128.2 ± 21.0*

59.2 ± 21.0***

22

296.0 ± 44.9

164.8 ± 29.7*

76.9 ± 28.0***

26

341.0 ± 52.5

237.9 ± 38.1

125.0 ± 39.0**

* for p<0.05; ** for p<0.01; *** for p<0.001 as compared to untreated tumour growth
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n = 20

Figure 13. ER27319 maleate effectively controls tumour growth in vivo.
Eight-week old athymic mice were injected with Cal33 cells (1 x 10 6) on each flank (2
tumours/mouse). Once tumours were palpable, ER27319 maleate was administered orally
at 10 mg/kg and 40 mg/kg doses daily. Tumours were measured twice weekly and
tumour growth was normalized for each individual tumour to its original untreated
tumour measurement for determination of the percent increase for each individual
tumour. The average percent increase of tumour volume for all 20 tumours per treatment
group was calculated and plotted along with the standard error. Asterisks indicate a
statistically significant difference from untreated control tumour growth (p < 0.05).
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6

DISCUSSION
HNSCC affects approximately 600,000 new individuals each year, and includes

malignancies arising in the oral cavity, nasal cavity, lip, paranasal sinuses, salivary
glands, pharynx, and larynx [2]. Currently, treatment is limited to chemotherapy,
radiation therapy and/or surgery. High throughput drug screening has the potential to
identify highly active agents for the treatment of HNSCC, a malignancy that has not seen
improvement in its survival rates in decades, and is in desperate need of novel therapeutic
options.
In an effort to identify novel targets and pathways implicated in HNSCC, I
performed high throughput drug screening on a panel of HNSCC cell lines against 1,505
FDA-approved drug compounds. In addition, I screened a subset of HNSCC cell lines on
an expanded drug panel including an additional 1,825 compounds in an effort to identify
compounds with preferential activity in either HPV-positive or HPV-negative HNSCC
cell lines. Following my preliminary screen and identification of hit compounds, I then
selected 23 compounds to be confirmed as hits through generation of dose response
curves. Finally, two compounds, ER27319 maleate and NSC146109 hydrochloride were
selected as lead drug compounds to move forward into preclinical development.

6.1 Summary of Experimental Findings



Large-scale, high throughput drug screening identified highly active agents in
HNSCC cell lines.
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HNSCC cell lines are sensitive to known chemotherapeutic agents.



HNSCC cell lines are sensitive to drugs targeting known pathways and targets in
cancer.



High throughput screening identified highly active agents targeting novel cellular
targets in HNSCC.



Select HNSCC cell lines were less sensitive to chemotherapeutics.



Expanded screening identified compounds with preferential activity in either
HPV-positive or HPV-negative HNSCC cell lines



NSC146109 hydrochloride effectively inhibited HNSCC cell line growth in vitro.



Syk inhibitor, ER27319 maleate, potently suppressed HNSCC cell line
proliferation in vitro and in vivo.

6.2 Implications of Experimental Findings

6.2.1

High throughput drug screening identified highly active
agents in HNSCC cell lines including known therapeutics
and compounds targeting well-known pathways in cancer

Preliminary drug screening at a single concentration resulted in the identification
of 78 hit compounds that demonstrated activity against HNSCC cell lines in vitro. Many
of these highly active compounds affected cellular pathways and targets previously
implicated in cancer and even HNSCC specifically. Chemotherapeutic drugs such as
daunorubicin, doxorubicin, Actinomycin D, Etoposide and Taxol were found to be active
against HNSCC cell lines in vitro and have all been extensively explored and approved
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for the treatment of a variety of malignancies (Table 7). Having such chemotherapeutic
agents appear within the top drug hits helps to provide internal positive controls for my
high throughput screening experiments since drug compounds known and confirmed to
be effective at inhibiting cancer cell growth, are proving to be highly potent on this high
throughput platform.
Interestingly, although screening identified known chemotherapeutics among the
hit compounds, some of these clinically established drugs were found to be relatively less
potent that many other hit compounds (Appendix 2). For example, Taxol® (Paclitaxel,
NSC125973) is a compound commonly used for the treatment of breast, ovarian, and
non-small

cell

lung

cancers

as

well

as

head

and

neck

cancers

(http://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel). This compound has
been in clinical use for over 30 years and there are currently 2,482 clinical trials ongoing,
with 210 trials for its use in the treatment of head and neck cancers
(https://clinicaltrials.gov/ct2/results?term= Paclitaxel&Search=Search). Despite Taxol®
being identified as a hit compound; there were many additional compounds that appeared
as hits in the screen that had higher activity across the HNSCC cell line panel. In
addition, cisplatin and carboplatin, which are standard of care chemotherapeutics for
HNSCC, were included in my high throughput drug screening. However, neither drug
was found to be a hit when screened at a single dose of 4 μM. Since these drug
compounds are routinely used as the workhorses for the treatment of head and neck
cancers, the most likely explanation is that these drugs were not at optimal concentrations
to effectively control HNSCC cell line proliferation.
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Although this study was limited to in vitro experiments at a single drug
concentration for the characterization of drug potency of these established
chemotherapeutics in HNSCC cell lines, these results suggest that there are potentially a
multitude of currently uncharacterized compounds in HNSCC that may be significantly
more effective than current chemotherapeutics at controlling HNSCC growth and warrant
further investigation by our laboratory.
Next, I wanted to confirm the activity of a subset of drug compounds through
generation of dose response curves to characterize the sensitivity of each HNSCC cell
lines to the top 23 drug compounds selected for hit confirmation. Compounds selected for
hit confirmation were selected based on three criteria: universal potency, differential
activity and PI3K-pathway specific, and IC50 values were calculated. IC50 values provide
a valuable quantitative measure of the effectiveness of a drug compound at inhibiting a
specific biological or biochemical function. Overall, the methodology of high throughput
drug screening for drug hit identification and validation of top drug hits used in this study
proved successful as majority of the top compounds were confirmed as being moderately
(IC50 = 2 – 7.99 μM) to exquisitely sensitive (IC50 < 2 μM) across the entire HNSCC cell
line panel (Figure 9). Confirmation of drug activity is essential for determination of the
concentration of drug required for efficient control of HNSCC cell line proliferation in
vitro as well as to provide sufficient preclinical data prior to testing drug activity in vivo
using mouse xenografts.
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6.2.2

High throughput screening identified highly active agents
targeting novel cellular targets in HNSCC

In addition to identifying known chemotherapeutics, my large-scale screening
identified many highly active compounds targeting novel cellular targets within the cell.
The automated nature of the high throughput screen enabled me to screen over 3,300
compounds in total, which facilitated the identification of many novel targets that may
play a significant role in HNSCC including PAR1, CXCR2, p38α, EAAT2/4 and RARγ,
and others (Appendix 2, 3). Some of these targets have been previously explored in the
context of other diseases or even other malignancies, however, little to no evidence of
their role in HNSCC could be found in the literature. Further investigation into these
compounds and novel cellular targets is required to evaluate their efficacy and confirm
their activity in HNSCC.

6.2.2.1

Anthelmintics

Anthelmintics are a class of drugs that function by removing internal parasites
and/or parasitic worms from the body without causing any significant damage to the host
organism [35]. Many populations in developing nations suffer from such helminth
infections as well as their co-morbidities such as malnutrition, reduced immunity and
anemia [35]. Anthelmintic drugs have been observed to have impressive infection cure
rates anywhere from 76-98%, with most of these drugs having broad-spectrum
anthelmintic effects [35]. These drugs function with extremely high efficacy while being
relatively inexpensive in terms of drug cost [35]. Two main types of anthelmintics were
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identified as hits in my high throughput screening: benzimidazoles (including
albendazole, flubendazole, mebendazole and fenbendazole) and niclosamide (Appendix
3).
In recent years, the repurposing of drugs for alternate uses than what was
originally intended has become increasingly popular as investigators seek new treatment
options for different human diseases. Interestingly, investigations into anthelmintics for
the treatment of various cancers have proven highly promising. Flubendazole was
observed to effectively enhance cytotoxicity in breast cancer cells [36], mebendazole was
identified as a hit in a high throughput screen looking for compounds effective at
controlling colon cancer cell line growth [37] and niclosamide has been found to
effectively inhibit proliferation of human osteosarcoma cells as well as enzalutamideresistant prostate cancer cells [38, 39]. Additionally, anti-protozoals, which include
anthelmintic compounds, have been found to efficaciously kill cancer subtypes enriched
for stem-like properties [40]. These recent findings along with the results from my
expanded screening all support old/existing microbicides being further explored for the
potential repurposing as new cancer therapeutics to eradicate HNSCC cancer cells.

6.2.3

Select HNSCC cell lines were less sensitive to
chemotherapeutics

Following analysis of my preliminary drug screens, I observed that the HNSCC
cell lines SCC-4, PCI6A and SCC-25 all appeared to be less sensitive overall to the
majority of compounds included in my screens, with SCC-25 remaining relatively
insensitive even with my confirmatory dose response curves (Appendix 2, Figure 9).
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Review of the raw fluorescence data obtained for each of these cell lines found that they
all had similar readings to the other HNSCC cell lines tested thus indicating comparable
levels of cellular viability across all samples tested.
One possible explanation for this trend is that SCC-4 and SCC-25 were observed
to have increased doubling times than most of the cell lines screened, which could
account for certain compounds not appearing to be as effective while appearing highly
potent in the remainder of HNSCC cell lines tested. An increased doubling time would
infer that these cells are not going through as many rounds of the cell cycle, so
compounds affecting regulation of the cell cycle or cytoskeleton formation during
cellular division, which many of the top compounds do, may be less effective in such cell
lines. Other explanations for this insensitivity could be that the cellular health of these
specific HNSCC cell lines was poor and/or that these specific cell lines were
contaminated, however, cell line identity was confirmed with STR profiling prior to
screening and any bacterial contamination should have been obvious when screening as
addition of alamarBlue would result in an extremely positive outlier for metabolic
activity.

6.2.4

Expanded screening identified compounds with preferential
activity in HPV-positive or HPV-negative HNSCC cell lines

Based on what was previously known about HNSCC including the differing
etiologies of tobacco exposure and infection with HPV [15], I hypothesized that because
HPV-positive and HPV-negative HNSCC cell lines and xenografts are molecularly
distinct, they would respond differentially to a subset of therapeutic agents identified in a
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high throughput drug screen. Initially, I was forced to reject my null hypothesis since no
hit compounds from my preliminary screening of 1,505 compounds, were found to be
preferentially active in either HPV-positive or HPV-negative HNSCC cell lines.
However, when I subsequently performed a drug screen using an expanded panel of
1,825 drug compounds on a subset of HNSCC cell lines, I was able to identify
compounds that affected HPV-positive or HPV-negative cells exclusively (Table 8).

6.2.4.1

Hycanthone displayed preferential activity in HPV-positive
HNSCC cell lines

Hycanthone was identified in my expanded high throughput screen as being
preferentially active in HPV-positive HNSCC cell lines (Appendix 3). Since HPVpositive patients have been found to have better overall survival than their HPV-negative
counterparts, it is imperative that compounds targeting HPV-positive tumours specifically
are identified to help treat these patients since they will likely have to live with the
toxicities of their treatment. Hycanthone functions by intercalating into DNA and
inhibiting RNA synthesis and it has been found to be a potential anti-neoplastic agent.
Phase I clinical trials have been completed in advanced cancers [41], which are cancers
that are unlikely to be cured as well as advanced metastatic cancers [42] and a phase II
trial has been completed for hycanthone in advanced colorectal carcinoma [43]. One
potential explanation for its preferential activity in HPV-positive HNSCC cell lines is that
cells infected with HPV often depend on the expression and oncogenic function of HPV
oncoproteins E6 and E7, which target p53 and pRb, respectively, for degradation [4, 15].
This dependency on expression of E6 and E7 for tumourigenesis may also depend on
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increased rates of transcription, which could potentially explain why an inhibitor of RNA
synthesis was found to display activity in these HPV-positive cells. To date, hycanthone
has not been explored as a therapeutic option for HNSCC, thus opening up the possibility
for further investigation into its cellular mechanism of action and differential activity in
HPV-positive and HPV-negative HNSCC cells.

6.2.4.2

Compounds with preferential activity in HPV-negative
HNSCC cell lines

Conversely, 5 compounds were found to be hits in HPV-negative HNSCC cell
lines exclusively (Table 8). Upon review of the literature, I found limited evidence
examining the roles of 6-azauridine, an anti-viral agent, and primaquine diphosphate, an
anti-parasitic, in cancer. However, these compounds, along with many other drugs that
were identified as being extremely potent across all 6 cell lines in the expanded drug
screen, were found to be anti-parasitics (including anthelmintics) as well as antibiotics
(Appendix 3). A recent publication by Lamb and colleagues (2015) found that
puromycin, along with other antibiotics targeting protein translation, could suppress
cancer stem cells in culture and control the formation of tumourspheres [44].
Furthermore, others have observed that antibiotics targeting active sites of the ribosome
directly as well as indirect inhibitors of protein synthesis have an extensive cytotoxic
effect on breast cancer cells in vitro [40]. Cuyàs and colleagues (2015) concluded that
cancer subtypes that are enriched with properties of stem cells (such as the ability to
divide and renew themselves) exhibit an extreme sensitivity to antibiotics and antiprotozoals targeting protein synthesis [40]. These findings could help provide an
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explanation as to why many antibiotics (e.g. puromycin) and anti-protozoals (e.g.
albendazole) were observed to be active in my panel of HNSCC cell lines (Table 8,
Appendix 3).

6.2.5

NSC146109 hydrochloride effectively inhibited HNSCC cell
line growth in vitro

NSC146109 hydrochloride was identified as one of the top 10 most active
compounds in my high throughput drug screen (Appendix 2). NSC146109 hydrochloride
is an activator of p53 that has been found to activate p53 transcription, increase levels of
p53 in tumour cells and protect p53 from E3 ubiquitin-protein ligase (Mdm2)-mediated
degradation [33]. To ensure that this compound was controlling HNSCC cell line
proliferation in vitro by this cellular mechanism, I attempted to look at TP53 transcript
levels using quantitative RT-PCR. Unfortunately, TP53 transcript levels were too low to
be accurately detected and compared (Figure 11). In addition, a suitable positive control
was not obtained and I was therefore unable to normalize the untreated samples in order
to gain an understanding of baseline TP53 transcript levels within HNSCC tumour cells.
Currently, I am attempting to use normal, non-cancerous human cell lines as a
positive control to redo the RT-PCR experiment to see if I can get a better measure of
TP53 levels in untreated cell lines and subsequently, using the now normalized untreated
TP53 transcript levels to compare to NSC146109 hydrochloride-treated cells with the
expectation of TP53 transcript levels increasing.
Next, I plan to investigate p53 levels at the protein level using Western blot
analysis where I will compare levels of p53 protein in treated cells versus untreated cells.
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Examination of p53 protein enables conclusions to be drawn regarding levels of p53 at
the functional level since this is the molecule that acts as an essential tumour suppressor
within the cell. Looking exclusively at TP53 transcript levels is not a direct measurement
of levels of p53 protein, which is why investigation into p53 protein levels upon
treatment with NSC146109 hydrochloride is essential to confirm its mechanism of action
within the cell.
Finally, I will examine cellular levels of p21 in response to reactivation of p53 as
p21 is a well-documented downstream functional target of p53 activation [45, 46]. P21 is
a potent and universal inhibitor of cyclin-dependent kinases and functions as a regulator
of cell cycle progression [47]. Increases in p53 have been found to result in increased
levels of p21, which inhibits the proliferation of mammalian cells [45, 47]. Since
NSC146109 hydrochloride functions to reactivate p53 within the cell by protecting it
from Mdm2-mediated degradation, I expect increased levels of p53 protein within the
cell along with increased levels of its downstream target p21, upon treatment of HNSCC
cells with this compound.
Testing of NSC146109 hydrochloride using in vivo cell line xenografts was
intended, however, there were issues with the solubility of the compound when
attempting to resuspend it for intraperitoneal dose delivery in mice. This issue is currently
being examined where I am pursuing different reagents (e.g. DMSO, ethanol) in varying
concentrations in an attempt to solubilize NSC146109 hydrochloride at concentrations
suitable for in vivo mouse xenograft experiments.
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6.2.5.1

TP53 and Cancer

TP53, which encodes p53 protein, is one of the most well known tumour
suppressor genes in cancer and is mutated or lost in approximately 50% of all human
malignancies [48]. As the “guardian of the genome”, p53 regulates cell cycle progression
by initiating G1-arrest in response to DNA damage and loss of functional p53 results in
unregulated cellular division, or cancer cell formation [48]. A recent genomic
characterization of HNSCC reported the frequency of p53 mutations and/or deletions at
84% in HPV-negative HNSCC tumours and 3% HPV-positive tumours [20].
Interestingly, disruptive mutant p53 has been found to be correlated with decreased
recurrence-free survival as well as a valuable predictive biomarker in the development of
local recurrences compared to patients with non-disruptive mutations or wild-type TP53
[49, 50, 51].
Investigations into small molecule activators of p53 have found that these
compounds can induce apoptosis and enhance cytotoxicity in HNSCC cell lines [52].
Compounds such as nutlin-3, RITA, CP-31398, PRIMA-1 and Minnelide™ have all been
shown to successfully control HNSCC cell line proliferation in vitro against HNSCC cell
lines through reactivation of p53 [52, 53]. Although these compounds have proven
successful in vitro and in select preclinical models of HNSCC [52], there are currently no
clinical trials investigating such compounds in head and neck cancer, thus providing a
potential opportunity to explore this target as a treatment for patients suffering from
HNSCC.
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6.2.6

ER27319 maleate suppressed HNSCC cell line proliferation
in vitro and controlled tumour growth in vivo

In addition to NSC146109 hydrochloride, the compound ER27319 maleate was
also selected for preclinical development due to its high activity in HNSCC cell lines.
ER27319 maleate has been found to inhibit phosphorylation of spleen tyrosine kinase
(Syk) within the cell [34, 54]. In order to verify that ER27319 maleate is controlling
HNSCC cell line proliferation through inhibition of Syk phosphorylation, both
endogenous and phosphorylated Syk were examined in both treated and untreated
HNSCC cells. Syk has 3 different sites that can undergo phosphorylation (Tyr323;
Tyr525/526), all of which may be affected upon treatment with ER27319 maleate, so it
was important to attempt to look at all of these sites in my studies. Although observation
of endogenous Syk using Western blot analysis proved successful, I was unable to
effectively visualize phosphorylated Syk, particularly in the context of untreated HNSCC
cells and thus was unable to make any concrete conclusions regarding ER27319 maleate
inhibiting Syk phosphorylation in vitro (Figure 12).
Currently, I am attempting to boost universal cellular phosphorylation by growing
cells in serum-free media, which induces a stressed state and increases global
phosphorylation within the cell. By increasing cellular phosphorylation, I hope to elevate
phosphorylated Syk levels to levels that can be effectively visualized by Western Blow
analysis. Once phosphorylated Syk can be efficiently visualized through universal
amplification of cellular phosphorylation, comparisons between ER27319 maleate-treated
cells and untreated cells can be made to ensure that ER27319 maleate is in fact
controlling HNSCC cell line growth by inhibiting phosphorylation of Syk.
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Additionally, future studies with this compound will involve examination of both
endogenous and phosphorylated Syk levels across my entire panel of HNSCC cell lines.
Gaining a better understanding of total Syk and phosphorylated Syk levels in all 28
HNSCC cell lines will enable appropriate cell line selection for future experiments when
attempting to examine changes in Syk phosphorylation (i.e. examination of an HNSCC
cell line with increased levels of phosphorylated Syk in untreated cells may allow for an
visible and ideally indisputable inhibitory effect on Syk phosphorylation to be observed
upon addition of ER27319 maleate).
With the knowledge that ER27319 maleate could effectively control HNSCC cell
line proliferation in vitro, I wanted to examine the effect this compound had in an in vivo
cancer model using cell line xenografts. Mice treated with ER27319 maleate (40 mg/kg)
had significantly reduced tumour growth as compared to untreated control tumours
(Table 9, Figure 13). In addition, the compound was extremely well tolerated amongst all
animals tested as evidenced by subjective observation. Future experiments will involve
treating cell line xenografts with an increased dose of ER27319 maleate (70 mg/kg),
which was also found to be well tolerated, to see if I can further reduce tumour growth or
even stop tumour growth completely. This preliminary data helps support my findings of
ER27319 maleate demonstrating high activity both in vitro and in vivo in HNSCC cell
lines and opens up the possibility of further preclinical modeling of this compound
towards its development for the treatment of HNSCC.
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6.2.6.1

Spleen Tyrosine Kinase

Spleen tyrosine kinase (commonly referred to as Syk) is a member of the Syk
family of tyrosine kinases that has historically been associated with transmitting cellular
immune signals within B cells in the initiation of the immune response [55]. More
recently, Syk has been recognized as functioning as a promoter of cell survival in a
variety of different cell types [55]. Interestingly, Syk has also been found to promote cell
motility and progression in vitro in HNSCC cell lines [56]. Furthermore, an investigation
by Du and colleagues (2012) observed that Syk levels are elevated in nasopharyngeal
cancer and this was found to be correlated with poor patient prognosis thus presenting the
opportunity for a new prognostic biomarker [57].
ER27319 maleate was one of the top drugs uncovered in my high throughput drug
screening that displayed extremely high activity across all HNSCC cell lines tested. This
evidence of its ability to efficiently control HNSCC cell line proliferation both in vitro
and in vivo, combined with its newly associated role in epithelial cell motility and cell
cycle progression, presents the possibility of a new and promising therapeutic target in
HNSCC.
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6.3 Limitations to the Study
One of the major limitations of this study was the use of cell lines as a model of
HNSCC. Cell lines grow in a two dimensional monolayer in culture and are thus not the
best representation of a three dimensional patient tumour. In addition, due to their two
dimensional growth, cell lines are unable to replicate the tumour microenvironment, a
series of complex interactions that facilitate tumorigenesis including stromal interactions,
tumour vascularisation, various signaling molecules as well as the interactions with the
extracellular matrix. This lack of accurate tumour replication, including the tumour
microenvironment, does not enable us to assess drug delivery as well as drug metabolism
in the context of an actual tumour environment.
Another major limitation of my study was the number of drugs tested. In my high
throughput drug screen, libraries of 1,505 and 1,825 drug compounds were screened
against HNSCC cell lines. Although this screen is the largest for the number of drug
compounds performed to date, for HNSCC specifically, there is still the possibility that
many active compounds may have been missed due to their lack of presence in my
screen. Although not completely comprehensive, my drug screens were extremely
extensive when it comes to drug testing in HNSCC. Additionally, I was able to
successfully identify many novel agents that warrant further investigation for the
treatment of HNSCC.
An additional limitation was the readout assay used for my high throughput drug
screening. The alamarBlue viability assay, which provides a readout of cellular metabolic
activity, enabled me to perform high throughput drug screening on a large-scale at a
relatively low cost. Unfortunately, this assay does not give us any specific information on
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whether or not cells stop proliferating due to apoptosis or senescence, for example.
Additional assays could have been used as readouts for my screening such as caspase
assays, which look at apoptosis as well as β-galactosidase assays, which examine cellular
senescence, however, the reagents for these assays tend to be quite expensive.
Examination of the effects of the 23 drugs selected for hit confirmation using additional
readouts such as cellular senescence and apoptosis, as mentioned above, may provide
further insight into the mechanisms of actions of these compounds as well as be more
cost effective as compared to large-scale screening with these specific assays.
Finally, a major limitation of this study was that my large-scale drug screening
was only performed at a single drug concentration. Screening at a single dose was
necessary in order to test as many cell lines against the number of drugs that I screened;
however, it is very possible that some highly active compounds were not identified. Some
drugs may require increased doses for an anti-proliferative effect to be observed so it is
likely that some potentially potent compounds were missed due to the selected screening
dose not being in the optimal activity range for such compounds.

6.4 Future Directions
Further investigation is required for elucidation of the mechanisms of actions for
the top drug compounds identified in my high throughput screening. In addition,
combinational drug therapies will be explored using both data from my drug screening as
well as relevant background information regarding drug and cellular targets from the
literature. Combinational drug screening is important to overcome potential issues of

67

drug resistance as well as to identify possible synergistic drug effects. In addition, I plan
on testing top drug hits in patient-derived xenografts (PDX) models. PDX will enable me
to validate my in vitro screening and in vivo cell line xenograft model using actual patient
tumours. PDX have been found to maintain the genomic alterations of the original patient
tumour and have been found to be accurate in predicting patient response [58, 59].
The long-term goal of this project is to pair my drug sensitivity data to HNSCC
cell line genomic data in order to identify biomarkers of drug sensitivity and/or
resistance. The automated nature of this project has enabled a large number of HNSCC
cell lines to be screened against extensive chemical panels, which is crucial for providing
the statistical power required to make correlations between drug response and genetics.
There is currently a lack of reliable predictive biomarkers for treatment response in
HNSCC. One reason for this is due to the heterogeneity of HNSCC tumours, which
makes it difficult to identify patient cohorts that can predict responses to particular
therapeutics. In an effort to overcome this issue, it is essential that a large number of drug
compounds are screened so active compounds can be identified. As well, it is vital that an
extensive number of HNSCC cell lines are screened against these large chemical libraries
so conclusions regarding markers of drug sensitivity and/or resistance can be accurately
made.
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7

CONCLUSIONS
High throughput drug screening identified therapeutic agents that are highly

active in a panel of HNSCC cell lines. My screen of 1,505 compounds, along with an
expanded screen of 1,825 drugs against a subset of HNSCC cell lines, identified both
known and novel targets in HNSCC. Additionally, 23 compounds were confirmed as
being highly active in HNSCC cell lines in vitro through the generation of 10-point dose
response curves. One of these compounds, ER27319 maleate, an inhibitor of Syk
phosphorylation, was found to reduce tumour growth in vivo in a cell line xenograft
model.
Further

investigations

need

to

be

performed

to

systematically

and

comprehensively characterize each compound as well as its ability to control HNSCC cell
line and tumour growth in vitro and in vivo, respectively. In addition, my drug sensitivity
data will eventually be paired with cell line genomic analyses to facilitate the
identification of genetic biomarkers of drug response. Once combined, this strategy of
high throughput drug screening paired with genomic analysis has the potential to not only
identify novel agents to improve outcomes in HNSCC, but also identify ideal patient
populations to offer each drug to, thus delivering the goal of precision medicine to
HNSCC.
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Appendix 1. STR profiles of HNSCC cell lines used for screening.
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A23187, free
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Homoharrington
ine
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Daunorubicin
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Doxorubicin
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Anisomycin
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Calmidazolium
chloride
Ro 31-8220
mesylate
ER 27319
maleate
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Paxilline
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TCS3212
dihydrochloride
Cycloheximide
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Foretinib
Vincristine
sulfate
Colchicine
Vinblastine
sulfate
Taxol
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FCCP
Mycophenolic
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Etoposide
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Appendix 2. Drug hits identified by high throughput drug screening in HNSCC cell
lines.
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KF 38789
Cytochalasin D
S-Trityl-Lcysteine
Rottlerin
SB 225002
Y-26763
(Â±)-threo-3Methylglutamic
acid
Tacrine
hydrochloride
CMPD-1
Scopolamine
hydrobromide
Y-27152
Ki 8751
OLDA
DHBP
dibromide
NSC 3852
BADGE
D-AP7
PALDA

Reduction in cellular proliferation: red, 90-100%; orange, 80-90%; yellow, 70-80%; light green, 60-70%;
dark green, 50-60%; light blue, 40-50%; dark blue, 30-40%, purple, 20-30%; grey, <20%.
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Metampicillin sodium salt

Antibiotic

NIH/Prestwick

Metronidazole

Antibiotic

Prestwick

Thonzonium bromide

Antibiotic

NIH

Cephalexin monohydrate

Antibiotic

HMS-001

UM-SCC47

93-VU-147T

Target

D562

Drug

Cal27

Library

FaDu

Appendix 3. Drug hits (in red) from expanded drug panel screening.
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Prestwick

Thiostrepton

Antibiotic

Prestwick

Benzylpenicillin sodium

Antibiotic

NIH

Triptolide

NF-κB

Prestwick

Parthenolide

NF-κB

NIH

Clofazimine

Anti-inflammatory

NIH

Valdecoxib

Anti-inflammatory

NIH

Diphenylcyclopropenone

Topical Immunotherapy

NIH

Hydrocortisone

Immunosuppressant

NIH

Dipyridamole

Thrombus formation

NIH

Raclopride

Dopamine D2/D3 receptor

Prestwick

Thiethylperazine malate

Dopamine antagonist

Prestwick

Apomorphine hydrochloride
hemihydrate

Dopamine agonist

NIH

Rythmol

Antiarrhythmic

Prestwick

Ajmaline

Antiarrhythmic

Prestwick

Clofilium tosylate

Antiarrhythmic

NIH

Mosapride Citrate

5-HT4 agonist

NIH

5-Nonyloxytryptamine

5-HT1 eceptor

NIH

Tegaserod Maleate

5-HT4 agonist

Prestwick

Scoulerine

5-HT receptor

Prestwick

Chloropyramine hydrochloride

Antihistamine

Prestwick

Brompheniramine maleate

Antihistamine

Prestwick

Tranylcypromine hydrochloride

Histone demethylation

NIH

Azacitidine

DNA methylation

NIH

Cogentin Mesylate

Acetylcholine levels

Prestwick

Gallamine Triethiodide

Acetylcholine levels

NIH

Cerivastatin Na

Statin

NIH

Itavastatin Ca

Statin

NIH

Methyltestosterone

Oral steroid

Prestwick

Fluorometholone

Corticosteroid

Prestwick

Methyldopate hydrochloride

Anti-hypertensive

NIH

Fenoldopam Mesylate

Anti-hypertensive

NIH

LY 171883

PPARα/PPARγ

NIH

Rosigltazone HCl

PPARγ

NIH

Valaciclovir Hydrochloride

Anti-viral

NIH

6-Azauridine

Anti-viral

NIH

Fluphenazine HYDROCHLORIDE

Anti-psychotic

Prestwick

Thioridazine hydrochloride

Anti-psychotic

Prestwick

Benzethonium chloride

Anti-microbial

Prestwick

Ciclopirox ethanolamine

Anti-fungal

NIH/Prestwick

Itraconazole

Anti-fungal

Prestwick

Primaquine diphosphate

Anti-parasitic

Prestwick

Methimazole

Anti-thyroid

Prestwick

Fenoterol hydrobromide

Adrenergic agonist
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Prestwick

Proxyphylline

Xanthine derivative

Prestwick

Strophantine octahydrate

Cardiac glycosides

NIH/Prestwick

Tomelukast

Antiasthmatic

NIH

Tiagabine HCl

Anti-convulsive

NIH

Rosiglitazone Maleate

Anti-diabetic

NIH

Ranitidine hydrochloride

Histamine H2 receptor

NIH

Toremifene Citrate

Estrogen receptor

NIH

Tetraethylthiuram Disulfide

Alcohol dehydrogenase

Prestwick

Disulfiram

Acetaldehyde dehydrogenase

NIH

Procaine hydrochloride

Na+ channel

NIH

Pyrimethamine

MATE transporters

Prestwick

Omeprazole

Proton Pump Inhibitor

Prestwick

Quinacrine dihydrochloride dihydrate

MAO-A/B inhibitor

Prestwick

Letrozole

Aromatase Inhibitor

Prestwick

Bucladesine sodium salt

Phosphodiesterase inhibitor

Prestwick

Proscillaridin A

Na+/K+ ATPase

NIH/Prestwick

Moxisylyte hydrochloride

α-blocker

NIH

Bifemelane

Antidepressant (MAO)

NIH

Hydrochlorothiazide

Diuretic

NIH

3-hydroxy-1,2-dimethyl-4(1H)pyridone

Iron chelator

Prestwick

Chelidonine monohydrate (+)

Unknown

NIH

1H-CAS

Unknown

Prestwick

Methotrimeprazine maleate salt

Unknown

Prestwick

Chrysene-1,4-quinone

Unknown
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Appendix 4. Ethics approval for in vivo cell line xenograft model.
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